We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » Lantheus to Pay POINT Biopharma $260M for Two Late-Stage Cancer Treatments
Lantheus to Pay POINT Biopharma $260M for Two Late-Stage Cancer Treatments
Lantheus, which specializes in radiopharmaceutical diagnostic and therapeutic products, will pay $260 million in upfront license fees — with potential for another $1.8 billion — for worldwide rights to two of POINT Biopharma’s late-stage cancer therapeutic candidates.
To View This Article:
Login
Subscribe To Device Daily Bulletin Premium
Device Daily Bulletin Premium Subscription
Upgrade to Device Daily Bulletin Premium to get all the articles in the free publication PLUS more in-depth stories on regulatory and industry developments, FDA inspection and enforcement activities and analysis of market trends. It makes sense of everything successful devicemakers must know and do, delivering the news, analysis and interpretation of industry changes you need to stay compliant and thrive. And it’s combined with timely content from FDAnews management reports and webinars. Learn more